Nachrichten zur Arbutus Biopharma Corp Aktie

Arbutus Biopharma: Focused On HBV With A Potentially Huge Litigation Wildcard

…

Arbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty Remains

…

Moderna: Lizenzgebühren an Arbutus im Fokus - Aktienanalyse

New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Jefferies & Co: Michael Yee, Analyst von Jefferies & Co, rät in einer aktuellen Aktienanalyse…

Arbutus Biopharma jumps after claim construction order in patent fight with Moderna

…

Earnings call: Arbutus Biopharma outlines HBV strategy and financial health By Investing.com

Earnings call: Arbutus Biopharma outlines HBV strategy and financial health…

Antisense and RNAi Therapeutics Market Size & Share Envisaged To Reach USD 18.43 Billion By 2032, at 17.8% CAGR Growth: Polaris Market Research

The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It…

Arbutus Biopharma gains after Markman hearing on Thursday in Moderna dispute

…

Arbutus Biopharma reports 2023 cash position of ~$132M as of Dec. 31, 2023

…

Arbutus Biopharma and Barinthus Bio Present Preliminary Data from Phase 2a Clinical Trial Combining Imdusiran with VTP-300 at AASLD - The Liver Meeting®

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline…

Arbutus Biopharma Q3 2023 Earnings Preview

…

Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 16.67% and 7.39%, respectively, for the quarter ended June 2023. Do the…

Arbutus Reports Second Quarter 2023 Financial Results and Corporate Update

Regulatory approval received in New Zealand to advance AB-101, our oral PD-L1 inhibitor, into a Phase 1 clinical trial with…

Form 8-K Arbutus Biopharma Corp For: Aug 03

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Arbutus to Report Second Quarter 2023 Financial Results and Provide Corporate Update

WARMINSTER, Pa., July 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging…

Arbutus Appoints Melissa V. Rewolinski, PhD to its Board of Directors

WARMINSTER, Pa., July 12, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a…

Form 8-K Arbutus Biopharma Corp For: Jul 11

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Arbutus Biopharma appoints Karen Sims as chief medical officer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year....…

Arbutus Doses First Patient in Additional Treatment Arm of Phase 2a Triple Combination Clinical Trial that Includes a PD-1 Monoclonal Antibody

Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®)...…

Form 8-K Arbutus Biopharma Corp For: Jun 21

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023

Treatment was generally well tolerated with continued HBsAg declines in some patients...…

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year....…

Form 8-K Arbutus Biopharma Corp For: Jun 07

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Arbutus to Present AB-729 and AB-836 Data at EASL Congress 2023

WARMINSTER, Pa., June 07, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging…

Arbutus to Present at Jefferies Healthcare Conference

WARMINSTER, Pa., May 31, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a…

Form 8-K Arbutus Biopharma Corp For: May 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Arbutus to Present at JMP Securities Life Sciences Conference

WARMINSTER, Pa., May 09, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a…

Arbutus Biopharma Q1 Exceeds Consensus View; Cuts Cash Burn Guidance

Arbutus Biopharma GAAP EPS of -$0.10 beats by $0.04, revenue of $6.7M beats by $0.67M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Arbutus Biopharma Q1 2023 Earnings Preview

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Arbutus Provides AB-729 Clinical Data and AB-161 Preclinical Data as Oral Presentations at the Global Hepatitis Summit 2023

Seven patients with cHBV remain off all treatment and continue to maintain low levels of HBV DNA and HBsAg for…

dpa-AFX ProFeed